| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 30 May 2025 | 13 May 2025 |
| Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve Notice of Board Meeting / Closure of Trading Window Outcome of Board Meeting (As Per BSE Announcement Dated on 31.05.2025) | ||
| Board Meeting | 14 Feb 2025 | 30 Jan 2025 |
| VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) 2015 further to our letter dated 26.12.2024 we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on 14th day of February 2025 at Hyderabad inter alia to consider and approve un-audited Financial Results (Standalone & Consolidated) of the company for the Quarter and nine months ended December 31 2024. Further we would like to inform that pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the company has intimated its Designated Persons including Directors regarding the closure of trading window from 01.01.2025 to till 48 hours after the declaration of un-audited Financial Results (Standalone & Consolidated) of the company for the Quarter and nine months ended December 31 2024. Q3 Results FY2025 (As Per Bse Announcement Dated on 14.02.2025) | ||
| Board Meeting | 10 Jan 2025 | 6 Jan 2025 |
| VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/01/2025 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) 2015 we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on Friday 10th Day of January 2025 at Hyderabad inter alia to consider and approve un-audited Financial Results (Standalone & Consolidated) of the company for the quarter and half year ending 30th September 2024 any other items. ResultsQ1FY2025 (As Per BSE Announcement Dated on: 11/01/2025) | ||
| Board Meeting | 11 Dec 2024 | 11 Dec 2024 |
| Attached | ||
| Board Meeting | 14 Nov 2024 | 7 Nov 2024 |
| VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) 2015 further to our letter dated 06.09.2024 we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday14th Day of November 2024 at Hyderabad inter alia to consider and approve (1) audited Financial Results (Standalone & Consolidated) of the company for the quarter and year ended 31st March 2024 (2) Board Report (3) AGM for FY2024 & related matters. | ||
| Board Meeting | 6 Sep 2024 | 23 Aug 2024 |
| VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/09/2024 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) 2015 further to our letters dated 19.03.2024 & 17.05.2024 we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on Friday 06th Day of September 2024 at Hyderabad inter alia to consider and approve (1) audited Financial Results (Standalone & Consolidated) of the company for the quarter and year ended 31st March 2024 (2) Board Report (3) AGM for FY2024 & related matters. Further we would like to inform that pursuant to the SEBI (Prohibition of Insider Trading) Regulations the company has intimated its Designated Persons including Directors regarding the closure of trading window from 01.04.2024 to till 48 hours after the declaration of audited Financial Results (Standalone & Consolidated) of the company for the quarter and year ended 31st March 2024. The Board of Directors of the Company at its meeting held on September 06, 2024 inter alia, have approved / resolved/ taken note of the following: 1. Deferment for declaring the audited financial results for the FY 2024, owing to paucity of time for completing the Audit as the new statutory auditors M/s. SVRL & Co. have been appointed in the EGM held on 14.08.2024 2. To file an application to the office of the Registrar of Companies, Bangalore, Karnataka, seeking an extension of time by three months for the convening of AGM for the Financial Year 2023-24 Due to the above reasons unable to publish the Financial Results of the Company along with all other documents as per the provisions of Regulation 33 of SEBI (LODR) Regulations, 2015). The Board Meeting concluded at 5.00 P.M. (As per BSE Announcement dated on 06/09/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.